A pilot study of multicriteria decision analysis for valuing orphan medicines

Value in Health

Volumn 16, Issue 8, 2013, Pages 1163-1169

  Sussex, Jon ^a   Rollet, Pierrick ^b   Garau, Martina ^a   Schmitt, Claude ^b   Kent, Alastair ^c   Hutchings, Adam ^d  

^a OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GENETIC ALLIANCE UK   (United Kingdom)

^d Global Market Access Solutions LLP   (United Kingdom)

Author keywords

HTA bodies; methods; orphan drugs; payers; rare diseases

Indexed keywords

ORPHAN DRUG;

ARTICLE; CAREGIVER BURDEN; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FUNDING; HEALTH CARE ORGANIZATION; HUMAN; MULTICRITERIA DECISION ANALYSIS; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RARE DISEASE; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

HTA BODIES; METHODS; ORPHAN DRUGS; PAYERS; RARE DISEASES;

CAREGIVERS; COST OF ILLNESS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; PATIENTS; PILOT PROJECTS; QUALITY OF LIFE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84890312186     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.10.002     Document Type: Article

References (21)

1. N. Devlin, and J. Sussex Incorporating Multiple Criteria in HTA - Methods and Processes 2011 Office of Health Economics London
2. C. Runge Separating the wheat from the chaff Eur J Health Econ 13 2012 121 126
3. Department of Health A New Value-Based Approach to the Pricing of Branded Medicines - A Consultation 2010 Department of Health London
4. M. Garau, and J. Mestre-Ferrandiz Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries (OHE Briefing 52) 2009 Office of Health Economics London
5. J. Sussex, A. Towse, and N. Devlin Operationalizing value-based pricing of medicines: a taxonomy of approaches Pharmacoeconomics 31 2013 1 10
6. European Medicines Agency Benefit-Risk Methodology Project Work Package 4 Report: Benefit-Risk Tools and Processes 2012 European Medicines Agency London
7. Commissioning Board NHS Standard Operating Procedures: The Cancer Drugs Fund (CDF) Guidance to Support Operation of the CDF in 2013-14 2013 NHS Commissioning Board Leeds, UK
8. P. Thokala, and A. Duenas Multiple criteria decision analysis for health technology assessment Value Health 15 2012 1172 1181
9. Advisory Group for National Specialised Services. Decision-making framework for making recommendations on national commissioning. Available at: http://www.specialisedservices.nhs.uk/library/27/Decision-Making-Framework.pdf. [Accessed April 2, 2013].
10. National Institute for Health and Care Excellence Interim Methods of the Highly Specialised Technologies Programme Public Board Meeting and NICE Question Time 22 May 2013 - Agenda and Papers. Item 08 2013 National Institute for Health and Care Excellence London, UK
11. Scottish Government. Medicines fund 14/01/2013. Available at: http://www.scotland.gov.uk/News/Releases/2013/01/medicines-fund14012013. [Accessed April 3, 2013].
12. EU Committee of Experts on Rare Diseases. EUCERD recommendation for a CAVOMP information flow. 2012. Available at: http://www.eurordis.org/sites/ default/files/cavomp.pdf. [Accessed April 2, 2013].
13. E. Winquist, C.M. Bell, and J.T.R. Clarke An evaluation framework for funding drugs for rare diseases Value Health 15 2012 982 986
14. A. Denis, S. Simoens, and C. Fostier Policies for Orphan Diseases and Orphan Drugs KCE (Belgian Health Care Knowledge Centre) Reports 112C 2009 KCE Brussels, Belgium
15. W. Hughes-Wilson, A. Palma, and A. Schuurman Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 7 2012 74
16. National Institute for Health and Care Excellence Guide to the Methods of Technology Appraisal 2013 2013 National Institute for Health and Care Excellence London, UK
17. Kolassa EM. The Strategic Pricing of Pharmaceuticals. http://www.pondhousepress.com/ [Online]: PondHouse Press, 2009
18. M. Johannesson, B. Jönsson, and L. Jönsson Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective? (OHE Briefing 51) 2009 Office of Health Economics London
19. K.K. Shah Severity of illness and priority setting in healthcare: a review of the literature Health Policy 93 2009 77 84
20. C. Green, and K. Gerard Exploring the social value of health care interventions: a stated preference discrete choice experiment Health Econ 18 2009 951 976
21. J.F.P. Bridges, A.B. Hauber, and D. Marshall Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force Value Health 14 2011 403 413